MedTrace Logo

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

NCT03592264 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-10-15

No results posted yet for this study

Summary

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.

Conditions

Interventions

DRUG

OBI-3424

liquid formulation for Intravenous infusion

Sponsors & Collaborators

  • OBI Pharma, Inc

    lead INDUSTRY

Principal Investigators

  • Apostolia Tsimberidou, MD, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2024-02-13
Completion
2024-03-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03592264 on ClinicalTrials.gov